Penn State engineer aims to tackle COVID-19 from two angles

Research Alert

Newswise — UNIVERSITY PARK, Pa. — To combat COVID-19 in both the treatment and testing arenas, Yong Wang, Penn State professor of biomedical engineering, has received two grants from the Huck Institutes of the Life Sciences COVID-19 multi-institute seed grant fund.

Wang will use the testing grant to look at the creation of a COVID-19 analysis potentially capable of producing results that could be easily read in minutes. Wang will serve as the primary investigator for the project.

“(Our goal is to) use a very high strong signal to definitively display results to the person administering the test, even if they're not specifically trained,” Wang said. “With this method, at a drive-up testing site, the testers could have the person pull over in their car and wait a few minutes to find out if they are COVID-19 positive.”

Wang’s method involves detection of COVID-19 RNA — the virus’ genetic material — with a portable handheld fluorometer, which uses magnetic beads of iron oxide to extract the RNA.

“The current tests take a long time, require a complicated process, and may not be accurate,” Wang said. “When there are millions of people who need to be diagnosed, you want it to be ready for a very fast examination, that gives a clear signal quickly.”

The most common current method of COVID-19 testing, polymerase chain reaction (PCR), adds enzymes to jump-start a chemical process to enable detection of RNA in nasal swab samples. Sometimes during this process, the enzymes can lose their bioactivity and cause false negative results. Another issue with the tests is that a highly trained individual is needed to read the data to determine the results.

With Wang’s proposed test, special equipment would not be required either, something Wang said would give the test a unique portability.

“Since we plan to do tests at room temperature with simple technology, you wouldn't have to get test results in a laboratory. You can do it in the field,” Wang said. “You can quickly test people on a cruise ship, you can do tests in a parking lot and just about anywhere, so there are a lot of advantages to this method.”

The other seed grant Wang received is for a potential treatment method focused on suppressing cytokine storms in the lungs of patients induced by COVID-19. A cytokine storm, or cytokine release syndrome, is a severe immune reaction where the immune system releases too many cytokines into the blood too quickly. Cytokines are messenger proteins, requesting more or less immune activity depending on the situation. Releasing too many into the blood causes the immune system to overreact and attack healthy tissues, leading to organ damage and even death.

Wang is working with a co-primary investigator, Troy Sutton, Penn State assistant professor of veterinary and biomedical sciences, on this grant. They aim to suppress cytokine storms via living cells and a new cell delivery mechanism.

“Once COVID-19 patients enter intensive care units, pretty much you can only do one thing to keep them alive, and that’s provide oxygen via ventilators,” Wang said. “For full recovery, we have to rely on the patient’s immune system. But the immune system is in chaos due to COVID-19, so we have to rely on something that will allow the immune system to go back to normal.”

In the next three months, Wang and Sutton will collect preliminary data to demonstrate that their new system is able to calm the immune system in cell samples. After that, they will conduct animal studies to see if they can reduce immune activity and even reduce the amount of viral activity. Sutton’s expertise is in working in high containment with highly infectious respiratory pathogens, making him an ideal research partner for Wang.

“We hope to have the first step done within six months,” Wang said.

For Wang, helping humanity, such as fighting a pandemic, is why he became a biomedical engineer.

“Now is the time for us to help our fellow humans, to help our nation and to help our world,” Wang said.

Filters close

Showing results

1120 of 4595
Newswise:Video Embedded newswise-expert-panels-on-covid-19-pandemic-notable-excerpts-quotes-and-videos-available
Released: 19-Jan-2021 11:20 AM EST
Newswise Expert Panels on COVID-19 Pandemic: Notable excerpts, quotes and videos available

Newswise is hosting a series of Expert Panels discussion on unique aspects of the COVID-19 pandemic. This tip sheet includes some notable quotes from the panelists.

Newswise:Video Embedded cornell-to-help-train-new-york-s-pioneering-public-health-corps
Released: 19-Jan-2021 10:45 AM EST
Cornell to help train New York’s pioneering public health corps
Cornell University

Cornell University is partnering with New York state and Northwell Health System to develop and train the nation’s first state public health corps, which will support COVID-19 vaccination and improve long-term public health outcomes.

Newswise: LLNL and United Kingdom company to collaborate on development of universal coronavirus vaccine
Released: 19-Jan-2021 10:10 AM EST
LLNL and United Kingdom company to collaborate on development of universal coronavirus vaccine
Lawrence Livermore National Laboratory

ConserV Bioscience Limited (CBL) and Lawrence Livermore National Laboratory (LLNL) have agreed to collaborate on the development of a broad-spectrum or “universal” coronavirus vaccine.

Newswise:Video Embedded local-covid-19-strain-found-in-over-one-third-of-los-angeles-patients2
Released: 19-Jan-2021 8:05 AM EST
Local COVID-19 Strain Found in Over One-Third of Los Angeles Patients

A new strain of the coronavirus has been found in more than one-third of COVID-19 cases in Los Angeles and may be contributing to the acceleration of the recent surge of cases across Southern California, according to new research from Cedars-Sinai.

Newswise: Lockdown affords Aussie tennis players a unique advantage
Released: 18-Jan-2021 10:05 PM EST
Lockdown affords Aussie tennis players a unique advantage
University of South Australia

Australian-based tennis players may have a once-in-a-lifetime court advantage at the 2021 Australian Open as many of their international counterparts endure lockdown restrictions in Melbourne hotels.

access_time Embargo lifts in 2 days
Embargo will expire: 21-Jan-2021 12:00 AM EST Released to reporters: 18-Jan-2021 8:05 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 21-Jan-2021 12:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Jan-2021 5:05 PM EST
FLCCC Alliance issues public response to new NIH recommendation on the use of ivermectin
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

The Front Line COVID-19 Critical Care Alliance (FLCCC) has issued a public response to the National Institutes of Health (NIH) regarding the NIH COVID-19 Treatment Guidelines Panel’s “neither for nor against” recommendation for the use of ivermectin in the treatment of COVID-19.

Newswise: UCLA Fielding School of Public Health Researchers Say Mask Mandates Could add $1 Trillion to the U.S. GDP
Released: 18-Jan-2021 12:05 PM EST
UCLA Fielding School of Public Health Researchers Say Mask Mandates Could add $1 Trillion to the U.S. GDP
UCLA Fielding School of Public Health

The team, including UCLA Fielding School of Public Health professors Anne Rimoin and Christina Ramirez, found that near-universal adoption of nonmedical masks in public, combined with complementary public health measures, could successfully eliminate spread of the infection. and add $1 Trillion to the U.S. GDP.

Newswise: UCLA Researcher’s Team Finds Common Blood Pressure Medications do not Increase COVID-19 Risk
Released: 18-Jan-2021 12:05 PM EST
UCLA Researcher’s Team Finds Common Blood Pressure Medications do not Increase COVID-19 Risk
UCLA Fielding School of Public Health

Dr. Marc Suchard, of the UCLA Fielding School of Public Health, co-led international research team looking at two widely used types of blood pressure drugs.

Showing results

1120 of 4595